The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.


TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.

Research Programme

The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.  


If you have any questions you can fill in the form or mail us directly:


Dates announced Heart Failure 2021 congress (HFA-ESC)

Monitor this PAGE for more information on the scientific programme, call for science and registration.

Furthermore, the newly launched HFA Discoveries platform bundles the best available heart failure knowledge and the latest clinical advances. Watch on-demand webinars on Late-Breaking Science, and access clinical cases, important HFA position papers, and more.